New appointment in management of the Skolkovo Fund

Marek Dziki, former director of one of the oldest pharmaceutical companies Merck KGaA, was appointed as the Executive Director of the Biomedical Technologies Cluster of the Skolkovo Fund.

Marek Dziki achieved outstanding results in 20 years after starting his professional career in the global pharmaceutical industry as sales and marketing manager of German chemical and pharmaceutical group Merck KGaA.

Former Executive Director of the cluster Igor Goryanin left the post in June. Since then, the acting head of the biomedical cluster of Skolkovo is Chris Janssen, who is the Director of Science and Innovation in the cluster.

Having worked in Poland, and later in Germany, at the head office of Merck in Darmstadt as the Vice President and Director of Strategic Innovations, Marek was appointed as the managing director of two large companies of Merck in India in 2006.

Marek managed to achieve significant results in India as he doubling the sales of the company in this dynamically developing region.

Marek Dziki is a doctor of medicine, he received this degree at Medical University in Lublin, Poland in 1990. Marek received his Masters of Business Administration in Warsaw International Business School in 1996.

Merck is one of the largest pharmaceutical companies in the world, with its headquarters in Darmstadt, Germany. The revenue of the company in 2011 exceeded €10B, the net income was €985,1M. There are more than 40K people working in the company.